Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application

March 22, 2024 • Company Statements

Eisai announced an update on the regulatory review process of lecanemab by the European Medicines Agency (EMA). Additional details can be found in a news release available on Eisai’s website.

thumb
April 25, 2024
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human

Read More
thumb
April 24, 2024
Biogen Reports First Quarter 2024 Results
Read More